These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25582273)

  • 1. Vaccines 'on demand': science fiction or a future reality.
    Ulmer JB; Mansoura MK; Geall AJ
    Expert Opin Drug Discov; 2015 Feb; 10(2):101-6. PubMed ID: 25582273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.
    Deering RP; Kommareddy S; Ulmer JB; Brito LA; Geall AJ
    Expert Opin Drug Deliv; 2014 Jun; 11(6):885-99. PubMed ID: 24665982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines on demand, part II: future reality.
    Geall AJ; Kis Z; Ulmer JB
    Expert Opin Drug Discov; 2023 Feb; 18(2):119-127. PubMed ID: 36384351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of mRNA-based vaccines.
    Iavarone C; O'hagan DT; Yu D; Delahaye NF; Ulmer JB
    Expert Rev Vaccines; 2017 Sep; 16(9):871-881. PubMed ID: 28701102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
    Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plant-made immunogens and effective delivery strategies.
    Paul M; Ma JK
    Expert Rev Vaccines; 2010 Aug; 9(8):821-33. PubMed ID: 20673007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-amplifying mRNA vaccines.
    Brito LA; Kommareddy S; Maione D; Uematsu Y; Giovani C; Berlanda Scorza F; Otten GR; Yu D; Mandl CW; Mason PW; Dormitzer PR; Ulmer JB; Geall AJ
    Adv Genet; 2015; 89():179-233. PubMed ID: 25620012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agility in adversity: Vaccines on Demand.
    De Groot AS; Moise L; Olive D; Einck L; Martin W
    Expert Rev Vaccines; 2016 Sep; 15(9):1087-91. PubMed ID: 27389971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with messenger RNA (mRNA).
    Pascolo S
    Handb Exp Pharmacol; 2008; (183):221-35. PubMed ID: 18071662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine process technology.
    Josefsberg JO; Buckland B
    Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Messenger RNA-based vaccines: progress, challenges, applications.
    Kramps T; Probst J
    Wiley Interdiscip Rev RNA; 2013; 4(6):737-49. PubMed ID: 23893949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza vaccines: from whole virus preparations to recombinant protein technology.
    Huber VC
    Expert Rev Vaccines; 2014 Jan; 13(1):31-42. PubMed ID: 24192014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections.
    Parums DV
    Med Sci Monit; 2021 May; 27():e932915. PubMed ID: 33942804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA-based vaccines.
    Ulmer JB; Mason PW; Geall A; Mandl CW
    Vaccine; 2012 Jun; 30(30):4414-8. PubMed ID: 22546329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particles produced in plants as potential vaccines.
    Scotti N; Rybicki EP
    Expert Rev Vaccines; 2013 Feb; 12(2):211-24. PubMed ID: 23414411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future directions for the development of Chlamydomonas-based vaccines.
    Rosales-Mendoza S
    Expert Rev Vaccines; 2013 Sep; 12(9):1011-9. PubMed ID: 24053395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNA transcript therapy.
    Weissman D
    Expert Rev Vaccines; 2015 Feb; 14(2):265-81. PubMed ID: 25359562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.